+44 20 8123 2220
info@marketpublishers.com

Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth (Status and Outlook) 2023-2029

https://marketpublishers.com/r/G8CB62382FF0EN.html
Date: March 2023
Pages: 101
Price: US$ 3,660.00 (Single User License)
ID: G8CB62382FF0EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

AAV is transformed from a naturally occurring virus into a delivery mechanism for gene therapy. The viral DNA is replaced with new DNA, and it becomes a precisely coded vector and is no longer considered a virus, as most of the viral components have been replaced. The AAV Vector-Based Gene Therapy market size is anticipated to shoot up exponentially attributing to an increase in the approval of a growing number of gene therapies and readily adoption on approval, ability to treat a broad array of conditions, increasing prevalence of diseases, convenient one-time dosing approach and curative treatment options.

LPI (LP Information)' newest research report, the “Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry Forecast” looks at past sales and reviews total world Adeno-Associated Virus (AAV) Vector-Based Gene Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Adeno-Associated Virus (AAV) Vector-Based Gene Therapy sales for 2023 through 2029. With Adeno-Associated Virus (AAV) Vector-Based Gene Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Adeno-Associated Virus (AAV) Vector-Based Gene Therapy industry.

This Insight Report provides a comprehensive analysis of the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading

+44 20 8123 2220
info@marketpublishers.com

global companies with a focus on Adeno-Associated Virus (AAV) Vector-Based Gene Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy.

The global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Adeno-Associated Virus (AAV) Vector-Based Gene Therapy players cover BioMarin Pharmaceutical, Sangamo Therapeutics, Amicus Therapeutics, Roche, Pfizer, NightstaRx, MeiraGTx, Sarepta Therapeutics and Neurocrine Biosciences, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market by product type, application, key players and key regions and countries.

Market Segmentation:

+44 20 8123 2220
info@marketpublishers.com

Segmentation by type

- Single-stranded AAV (ssAAV)
- Self-complementary AAV (scAAV)

Segmentation by application

- Hemophilia
- Ophthalmology
- Lysosomal Storage Disorders
- Neurological Disorders
- Others

This report also splits the market by region:

- Americas
  - United States
  - Canada
  - Mexico
  - Brazil
- APAC
  - China
  - Japan

+44 20 8123 2220
info@marketpublishers.com

- Korea
- Southeast Asia
- India
- Australia

Europe

- Germany
- France
- UK
- Italy
- Russia

Middle East & Africa

- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

- BioMarin Pharmaceutical

+44 20 8123 2220
info@marketpublishers.com

Sangamo Therapeutics

Amicus Therapeutics

Roche

Pfizer

NightstaRx

MeiraGTx

Sarepta Therapeutics

Neurocrine Biosciences

Voyager Therapeutics

Asklepios Biopharmaceutical

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

11 KEY PLAYERS ANALYSIS

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth (Status and Outlook) 2023-2029

Product link: https://marketpublishers.com/r/G8CB62382FF0EN.html

Price: US$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G8CB62382FF0EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

+44 20 8123 2220
info@marketpublishers.com